# TB-500: What Changes If the Regulatory Status Changes

**By TelosRX Editorial Team** · 2026-09-21

**If TB-500's regulatory status changes, so does what telos rx can offer. Right now, the FDA's Category 2 bulk substance classification keeps standalone TB-500 out of reach for compounding pharmacies. That is why telos rx only offers TB-500 through the BPC-157 + TB-500 combination protocol. If that classification is ever revised, availability could change, but nothing about that has happened yet.**

The short answer

**Nothing changes today. Standalone TB-500 remains restricted, and telos rx's only TB-500 offering stays the BPC-157 + TB-500 combination protocol.** If the FDA revises its bulk substance list in the future, partner compounding pharmacies would need to update their own compliance posture before anything new could be offered. Patients interested in TB-500 today can pursue it through the [reviewed combination protocol](https://www.telosrx.com/pages/bpc-157-tb500).

[Start your BPC-157 + TB-500 combination visit →](https://start.telosrx.com/start-online-visit/peptides)

## What the current regulatory status actually is

In late 2023, the FDA classified TB-500 as a Category 2 bulk substance. That category is reserved for substances the agency has identified significant safety risk concerns about when used in compounding. The practical effect is straightforward: compounding pharmacies cannot legally prepare or dispense TB-500 on its own while that classification stands. This is a federal determination, not a state-level rule, so it applies uniformly to partner compounding pharmacies regardless of where a patient lives.

The FDA maintains an overview of how bulk substance compounding categories work, along with general compounding rules, on its [compounding questions and answers page](https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers). It is a useful reference for understanding the broader framework these categories sit inside.

## Why telos rx built the combination protocol around this rule

Because standalone TB-500 cannot be compounded, telos rx built its offering around a different, separately reviewed product. That product is the BPC-157 + TB-500 combination protocol, and it is not a workaround. It is a distinct compounded preparation that partner compounding pharmacies can legally prepare under current rules, and every claim made about it applies to the combination product specifically, not to TB-500 alone.

Patients sometimes ask whether this combination is simply a substitute for the standalone version. It is not framed that way here, and it should not be treated that way. It is its own offering, reviewed on its own terms, and it is the only route to TB-500 that telos rx currently provides.

**Key takeaway:** Regulatory categories can be revised, but nothing about TB-500's Category 2 status has changed since late 2023, and telos rx will not offer standalone TB-500 until it does.

## How bulk substance categories can change over time

FDA bulk substance lists are not permanently fixed. The agency periodically reviews nominated substances, and a Category 2 classification can, in principle, be revisited as new safety or manufacturing information becomes available. This is a normal part of how the compounding regulatory framework functions, and it applies to many substances beyond TB-500.

What this means in practice is that regulatory status is a snapshot, not a permanent rule. It reflects where things stand today. It does not predict what will happen next, and speculating about a specific timeline would not be responsible. Patients should treat any claim about an upcoming change with real skepticism unless it comes directly from the FDA.

## What would have to happen before standalone TB-500 became available

Even if the FDA revised TB-500's bulk substance category, that alone would not automatically put standalone TB-500 on telos rx's product pages. Partner compounding pharmacies would need to update their own internal compliance processes and confirm sourcing and testing protocols for the standalone peptide. Telos rx would also need to conduct its own review before offering it. Regulatory clearance is a precondition, not a launch announcement.

This is also why telos rx avoids language that implies standalone TB-500 is imminent or already in progress. No such change has occurred, and framing it that way would be misleading to patients trying to plan their care around accurate information.

## What stays the same regardless of regulatory changes

Some things about telos rx's approach to TB-500 are not tied to the current regulatory snapshot. The platform will continue to rely on licensed partner compounding pharmacies, asynchronous provider review before any preparation ships, and testing standards that apply to every compounded product on the platform. Those practices reflect how telos rx operates generally, not a temporary workaround for a specific substance's regulatory status.

Patients considering the BPC-157 + TB-500 combination protocol today do not need to wait on a regulatory change to access a reviewed, pharmacy-prepared option. The combination protocol is available now, through the same online intake process used for other telos rx products like [BPC-157](https://www.telosrx.com/pages/bpc-157) and [PT-141](https://www.telosrx.com/pages/pt-141).

## Why patients should be cautious about "regulatory change" claims from other sellers

TB-500's Category 2 status is a genuine point of confusion for many patients. Because of that, some sellers use vague or misleading language to suggest change is imminent, or has already happened, when it has not. Claims like "reclassification expected" or references to non-binding advisory discussions can create a false impression of certainty. The most reliable way to check current status is the FDA's own published bulk substance lists, not a seller's marketing copy.

TB-500 is derived from a peptide fragment called thymosin beta-4. For background on that broader research, the NIH's PMC database maintains a searchable index of published literature at [its thymosin beta-4 search results page](https://www.ncbi.nlm.nih.gov/pmc/?term=thymosin+beta+4). This is a good starting point for patients who want to understand the underlying science independent of any single seller's claims.

## How this differs from other peptides that have changed status

Regulatory status for compounded peptides is not static across the industry. Other substances have moved between categories over time as the FDA reviews new safety and sourcing information. That history is part of why patients reasonably ask about TB-500's status rather than assuming it is fixed forever. It also explains why telos rx frames its current TB-500 offering carefully, describing exactly what is available now rather than what might be available later.

It is worth separating two different kinds of change. One is a change in FDA bulk substance category, which is a formal regulatory action. The other is informal discussion, advisory commentary, or industry speculation about a substance, which carries no binding weight on its own. Patients should not treat the second kind as evidence that the first kind has happened or is about to happen.

## How to evaluate claims about pending regulatory changes

When a source claims TB-500's status is about to change, it is reasonable to ask where that claim comes from. A specific citation to an FDA notice, meeting record, or published rule carries real weight. A vague reference to "industry sources" or "insider information" does not. Patients researching this topic should treat the FDA's own published materials as the authoritative record, and treat everything else as secondary commentary at best.

This distinction matters. Acting on a false or premature claim about regulatory status could lead a patient to expect a product that is not actually available. It could also lead a patient to trust a seller who is not operating within current compounding rules. Careful sourcing of information about regulatory status is just as important as careful sourcing of the peptide itself.

## Why telos rx keeps this information current instead of speculative

Health platforms have an obligation to describe what is actually available, not what might eventually be available. That is especially true for a peptide like TB-500, where regulatory status directly determines whether a compounding pharmacy can legally act at all. Telos rx's editorial approach reflects that obligation: information about TB-500's status is checked against the FDA's own published materials, not assumptions or informal industry chatter.

This also means telos rx will not commit to a timeline for any future change in TB-500's classification, because no one outside the FDA is in a position to set that timeline. Any article, advertisement, or product description that claims otherwise should be treated with skepticism, regardless of the source.

## What to do if the status does change

If the FDA's classification of TB-500 changes, telos rx will update its own product and information pages. That update would happen once partner compounding pharmacies confirm they can meet the applicable sourcing and testing standards. Until then, the BPC-157 + TB-500 combination protocol remains the accurate, current option. It is reviewed the same way as any other compounded product telos rx offers.

[Start your BPC-157 + TB-500 combination visit →](https://start.telosrx.com/start-online-visit/peptides)

## Frequently Asked Questions

### Has TB-500's FDA classification changed recently?

No. TB-500 has been classified as a Category 2 bulk substance since late 2023, and that classification has not changed.

### What does Category 2 bulk substance status mean for TB-500?

It means compounding pharmacies are restricted from preparing or dispensing TB-500 on its own because the FDA has identified significant safety concerns about it in compounding.

### Does telos rx sell standalone TB-500?

No. Telos rx only offers TB-500 as part of the BPC-157 + TB-500 combination protocol, a separate, reviewed compounded preparation.

### If the FDA changes TB-500's status, will telos rx automatically start selling it alone?

Not automatically. Partner compounding pharmacies would need to update their compliance processes and telos rx would need to complete its own review before offering it.

### How can patients check TB-500's actual current regulatory status?

The FDA's own published bulk substance compounding lists and resources are the most reliable source, rather than claims made by individual sellers.

### Is the BPC-157 + TB-500 combination protocol available now?

Yes. It is available today through telos rx's standard online intake, provider review, and partner compounding pharmacy process.

_TelosRX is LegitScript-certified. Compounded medication is not FDA-approved and is prepared under federal compounding regulations. This article is general information, not medical advice, and does not replace guidance from your own provider. Approval is subject to evaluation by a licensed provider, and approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service._

Questions about eligibility? [Learn more about the BPC-157 + TB-500 combination protocol](https://www.telosrx.com/pages/bpc-157-tb500) or visit [TelosRX](https://telosrx.com).

**Tags:** bpc-157, peptides, tb-500

---

> Source: [Telos RX](https://www.telosrx.com/blogs/glp1/tb-500-what-changes-if-the-regulatory-status-changes)